ArticleFrontiers in microbiology2020
Re-sensitization of
Article in Frontiers in microbiology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
13 citing papers in PubMed, 17 citations in OpenAlex.
- CRISPRi knockdown of mycobacterial tkt gene potentiates the anti-mycobacterial activity of phyto-compounds from selected medicinal plants.BMC complementary medicine and therapies · 2025Article
- Mycobacterium susceptibility to ivermectin by inhibition of eccD3, an ESX-3 secretion system component.PLoS computational biology · 2025Article
- Harnessing CRISPR interference to resensitize laboratory strains and clinical isolates to last resort antibiotics.Scientific reports · 2025Article
- The CRISPR-dCas9 interference system suppresses inhA gene expression in Mycobacterium smegmatis.Scientific reports · 2024Article
- EfpA is required for regrowth ofAntimicrobial agents and chemotherapy · 2024Article
- CRISPR Interference-Mediated Silencing of theAntibiotics (Basel, Switzerland) · 2024Article
- Application of CRISPR-cas-based technology for the identification of tuberculosis, drug discovery and vaccine development.Molecular biology reports · 2024Review
- Non-replicative phage particles delivering CRISPR-Cas9 to target major blaCTX-M variants.PloS one · 2024Article
- Rapid Gene Silencing Followed by Antimicrobial Susceptibility Testing for Target Validation in Antibiotic Discovery.Methods in molecular biology (Clifton, N.J.) · 2024Article
- Identification of anti-Acta pharmaceutica Sinica. B · 2023Article
- Implementation of a mycobacterial CRISPRi platform in Mycobacterium abscessus and demonstration of the essentiality of ftsZTuberculosis (Edinburgh, Scotland) · 2023Article
- Tuberculosis conundrum - current and future scenarios: A proposed comprehensive approach combining laboratory, imaging, and computing advances.World journal of radiology · 2022Review
- CRISPR-Based Approaches for Gene Regulation in Non-Model Bacteria.Frontiers in genome editing · 2022Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 5 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
A greater understanding of the genes involved in antibiotic resistance in
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.